Top Markets
Coin of the day
Angion Biomedica Corp. Angion Biomedica Corp.

Angion Biomedica Corp.

ANGN
Clasificación en acciones #27858
Angion Biomedica Corp. operates as a biopharmaceutical enterprise,... Angion Biomedica Corp. operates as a biopharmaceutical enterprise, concentrating its efforts on the identification, advancement, and market introduction of small molecule treatments for severe organ damage and scarring conditions. Its primary investigational compound, ANG-3070, is an orally administered tyrosine kinase receptor inhibitor currently being developed to address fibrotic ailments, particularly those impacting the kidneys and lungs. The company's product pipeline also features ANG-3777, a hepatocyte growth factor mimetic engineered to treat acute organ injuries like delayed graft function, in addition to initiatives for ROCK2 inhibitors targeting fibrotic diseases and a CYP11B2 inhibitor program. Established in 1998, Angion Biomedica Corp. maintains its headquarters in Uniondale, New York.
Precio por acción
$1.00
Última sincronización: 2023-06-01
Capitalización bursátil
$30.11M
Cambio (1 día)
2.04%
Cambio (1 año)
0.00%
País
US
Comercio Angion Biomedica Corp. (ANGN)

Categoría

Ratio P/B de Angion Biomedica Corp. (ANGN)
Ratio P/B al 2026 TTM: 0
Según los informes financieros más recientes y el precio de las acciones de Angion Biomedica Corp., el ratio P/B actual (TTM) es 0. Al final de 2026, el ratio P/B era 0.
Historial del ratio P/B de Angion Biomedica Corp. desde 2026 hasta 2026
Ratio P/B al final de cada año
Año Ratio P/B Cambiar
Not enough data for the provided dates.
Ratio P/B de empresas similares o competidoras
Empresa Ratio P/B Diferencia del ratio P/B País
6.3419 -
US
3.7087 -
US
6.2413 -
NL
2.5054 -
AU
- -
CH